开发TIM-3抑制剂:克服癌症治疗中的免疫逃避
Lili Wang1,2,3, Hao Shen1,2,3, Binjian Jiang1,2,3
1State Key Laboratory of Natural Medicines and Jiangsu Provincial Key Laboratory of Targetome and innovative Drugs Medicines, China Pharmaceutical University, Nanjing 211198, China.
Journal of medicinal chemistry
|December 9, 2025
概括
新的小分子抑制剂向TIM-3 (T细胞免疫球蛋白和含有-3的粘素域) 显示出癌症免疫治疗的前景. 这项研究系统地审查了TIM-3机制和最近的小分子抑制剂开发,以改善癌症治疗.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 药用化学 医学化学
背景情况:
- 针对PD-1/PD-L1和CTLA-4的免疫检查点抑制剂已经在癌症治疗中取得了进展,但面临着有限的反应率和耐药性等挑战.
- 含有T细胞免疫球蛋白和粘素域-3 (TIM-3) 是一种新兴的免疫抑制受体,也是增强抗瘤免疫力的潜在目标.
- 目前TIM-3抑制剂的发展不平衡,许多基于抗体的药物处于后期试验阶段,而小分子抑制剂则滞后于临床前阶段.
研究的目的:
- 系统地审查TIM-3的结构和功能机制.
- 总结一下最近发现和开发小分子TIM-3抑制剂的进展.
- 突出化合物,并讨论新型TIM-3向剂的未来方向.
主要方法:
- 系统性文献审查,重点关注TIM-3结构功能和小分子抑制剂的开发.
- 通过虚拟选和合理设计识别的代表性化合物的分析.
- 讨论结构-活动关系研究和未来的研究途径.
主要成果:
- 蒂姆-3在免疫抑制中起着至关重要的作用,是瘤学中重要的治疗点.
- 最近在通过虚拟查和合理设计识别小分子TIM-3抑制剂方面取得了进展.
- 目前,研究碎片化和缺乏系统的结构-活性关系研究,阻碍了小分子TIM-3抑制剂的开发.
结论:
- 针对TIM-3的小分子抑制剂为克服当前免疫疗法的局限性提供了一个有希望的途径.
- 进一步的系统研究,包括结构-活性关系研究,对于推进小分子TIM-3抑制剂至关重要.
- 新型TIM-3向药物的开发可以显著改善抗瘤免疫力和癌症治疗患者的结果.
相关概念视频
Tumor Immunotherapy
1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
The Tumor Microenvironment
7.6K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
7.6K
Cancer Vaccines
932
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
932


